Our work identifies collagen and LAIR1 as a potential marker of PD-1/PD-L1 blockade resistance in lung cancer and validates multiple therapeutic targets in combination with immune checkpoint blockade. This evidence concerns the gene LAIR1 and lung carcinoma.